background
influenza
pneumonia
caus
high
mortal
everi
year
pandem
episod
kill
million
peopl
influenzarel
mortal
various
ascrib
ineffect
host
respons
fail
limit
viral
replic
excess
host
inflammatori
respons
result
lung
injuri
impair
ga
exchang
bacteri
superinfect
sought
determin
whether
lung
inflamm
promot
impair
host
surviv
influenza
pneumonia
method
find
distinguish
among
possibl
caus
influenzarel
death
induc
robust
lung
inflamm
expos
mice
aerosol
bacteri
lysat
prior
challeng
live
viru
treatment
induc
express
inflammatori
cytokin
tnf
bronchoalveolar
lavag
fluid
greater
respect
caus
lethal
influenza
infect
yet
augment
inflamm
associ
strike
resist
host
mortal
vs
surviv
p
reduc
viral
titer
p
bacteri
superinfect
viru
infect
lung
observ
mice
repeatedli
expos
bacteri
lysat
would
clinic
desir
influenza
epidem
tachyphylaxi
induc
viral
resist
bacteri
lysat
administ
viral
challeng
still
mortal
benefit
ribavirin
ad
aerosol
bacteri
lysat
host
surviv
synergist
improv
vs
surviv
conclus
togeth
data
indic
innat
immun
resist
influenza
effect
stimul
suggest
ineffect
rather
excess
inflamm
major
caus
mortal
influenza
pneumonia
annual
worldwid
mortal
associ
pneumonia
exce
infect
particular
influenza
pneumonia
annual
caus
death
unit
state
alon
beyond
impact
season
influenza
episod
pandem
influenza
account
mani
million
death
avian
influenza
alreadi
caus
human
death
worldwid
http
www
whointcsrdiseaseavianinfluenza
increas
global
sinc
suggest
eventu
humantohuman
transmiss
avian
influenza
may
caus
even
greater
lethal
infam
spanish
flu
viral
pathogen
includ
influenza
consid
potenti
agent
bioterror
mechan
underli
influenzarel
mortal
remain
controversi
progress
pneumonia
follow
insuffici
antivir
host
respons
one
possibl
caus
virallyinduc
excess
andor
dysregul
lung
inflamm
anoth
potenti
mechan
secondari
bacteri
infect
also
propos
primari
contributor
influenzarel
mortal
due
virallyinjur
epithelium
virusattenu
leukocyt
respons
recent
report
treatment
aerosol
lysat
nontyp
haemophilu
influenza
nthi
induc
profound
inflamm
lung
yet
strongli
protect
mice
otherwis
fatal
bacteri
pneumonia
induc
protect
phenomenon
known
stimul
innat
resist
stir
maxim
within
h
treatment
reli
recruit
neutrophil
resid
mast
cell
alveolar
macrophag
given
profound
induct
lung
inflamm
treatment
perceiv
opportun
determin
whether
host
inflamm
contribut
prevent
mortal
influenza
pneumonia
demonstr
despit
induc
inflamm
greater
observ
lethal
infect
anim
aerosol
nthi
lysat
result
remark
protect
otherwis
lethal
influenza
pneumonia
synergist
combin
antivir
medicin
postinfecti
treatment
togeth
data
suggest
ineffect
rather
excess
inflamm
major
caus
mortal
influenza
pneumonia
indic
innat
immun
resist
virus
therapeut
stimul
protect
popul
pandem
influenza
shown
profound
inflammatori
lung
respons
bacteri
lysat
improv
surviv
mice
infect
noncogn
bacteria
investig
effect
stimul
lung
mucos
innat
immun
surviv
influenza
pneumonia
mice
challeng
aerosol
influenza
ahong
ahk
univers
succumb
hemorrhag
pneumonia
unless
pretreat
aerosol
nthi
lysat
fig
treatment
reduc
mortal
deliv
day
prior
infect
deliv
day
prior
infect
lesser
degre
deliv
one
day
infect
fig
mortal
occur
within
day
viral
inocul
observ
day
infect
show
subsequ
mortal
protect
impart
aerosol
lysat
parallel
recoveri
bodi
weight
lost
earli
cours
infect
fig
lysateinduc
surviv
accompani
signific
reduct
viral
load
fourth
day
challeng
fig
sinc
prior
report
describ
poorer
outcom
associ
virusinduc
inflamm
compar
inflamm
induc
nthi
lysat
inflamm
induc
influenza
infect
inflamm
induc
combin
treatment
infect
figur
show
singl
repeat
treatment
nthi
lysat
induc
dramat
inflamm
lung
measur
cytokin
level
fig
cellular
influx
fig
remark
treatment
nthi
lysat
acut
induc
almost
tnf
infect
alon
treat
mice
actual
lower
level
inflammatori
cytokin
lung
day
infect
fig
time
treatment
nthi
lysateinduc
rise
cytokin
uninfect
mice
entir
resolv
data
shown
inflammatori
cell
infiltr
fallen
togeth
suggest
robust
earli
inflammatori
reaction
may
allow
rapid
resolut
infectioninduc
inflamm
notabl
intens
inflamm
observ
lung
seen
system
despit
increas
tnf
lung
respect
cytokin
increas
minim
transient
serum
fig
sinc
interferon
signal
essenti
baselin
host
antivir
resist
lung
investig
whether
treatment
nthi
lysat
capabl
induc
interferon
respons
addit
robust
induct
inflammatori
cytokin
found
nthi
lysat
treatment
also
induc
signific
increas
lung
interferon
c
level
fig
howev
unlik
tnf
fulmin
influenza
infect
observ
untreat
mice
actual
induc
higher
level
interferon
c
nthi
lysat
treatment
fig
presum
reflect
ongo
antivir
respons
host
contrast
better
contain
infect
treat
mice
character
lung
interferon
respons
nthi
lysat
assess
gene
express
use
whole
genom
microarray
analysi
maxim
resist
pneumonia
achiev
h
posttreat
compar
gene
express
sham
treat
mous
lung
mous
lung
h
posttreat
pathway
analysi
reveal
interferon
signal
among
upregul
event
follow
nthi
lysat
treatment
interferon
signal
pathway
transcript
report
tabl
show
treatment
induc
express
numer
transcript
critic
type
interferonab
type
ii
interferonc
signal
sinc
high
level
protect
influenza
viru
last
day
fig
prolong
protect
would
requir
repetit
dose
test
whether
tachyphylaxi
protect
effect
aerosol
nthi
lysat
occur
challeng
mice
influenza
three
differ
condit
lysat
treatment
singl
lysat
treatment
repetit
lysat
treatment
observ
mortal
untreat
group
found
ident
protect
nthi
lysat
treatment
whether
given
one
day
prior
infect
given
three
time
seven
four
one
day
prior
infect
fig
nthi
lysat
treat
group
protect
associ
recoveri
earli
weight
loss
fifth
day
infect
fig
observ
day
challeng
show
subsequ
mortal
altern
repetit
stimul
lung
innat
immun
prophylaxi
epidem
viral
infect
would
treat
proinflammatori
aerosol
infect
combin
antivir
drug
recent
found
treatment
highdos
aerosol
ribavirin
exposur
influenza
viru
provid
surviv
improv
mice
test
whether
two
intervent
might
effect
combin
mice
infect
influenza
viru
treat
ribavirin
alon
nthi
lysat
alon
combin
two
ribavirin
alon
improv
surviv
high
level
infecti
challeng
use
studi
howev
shown
figur
suspend
ribavirin
singl
dose
nthi
lysat
day
infect
improv
surviv
significantli
nthi
lysat
alon
vs
surviv
p
addit
nthi
lysat
treatment
day
almost
complet
protect
mortal
surviv
vs
control
untoward
effect
addit
protect
note
third
nthi
lysat
dose
ad
day
observ
day
show
subsequ
mortal
lower
respiratori
tract
infect
lead
caus
infecti
death
worldwid
recent
shown
stimul
innat
resist
stir
lung
induc
aerosol
bacteri
lysat
protect
mice
otherwis
fatal
bacteri
pneumonia
show
treatment
prevent
viral
pneumonia
despit
induct
lung
inflam
mation
greater
magnitud
observ
lethal
infect
influenzainduc
excess
andor
dysregul
lung
inflamm
recent
describ
mechan
pandem
infect
caus
mortal
consequ
observ
consider
effort
invest
attempt
improv
outcom
influenzainfect
mice
genet
pharmacolog
suppress
inflammatori
cytokin
product
contrast
current
previou
data
demonstr
robust
inflamm
associ
induct
protect
host
respons
fig
previous
shown
repetit
treatment
result
diminish
inflammatori
respons
without
loss
protect
possibl
cytokin
respons
protect
effect
howev
like
previou
observ
protect
bacteri
pathogen
proinflammatori
pretreat
result
signific
reduct
pathogen
burden
repres
decreas
viral
titer
fig
interferon
signal
associ
surviv
viral
bacteri
infect
observ
augment
type
ii
interferon
signal
nthi
lysat
treatment
figur
b
tabl
support
hypothesi
also
import
element
antivir
stir
explor
futur
one
manner
host
respons
nthi
lysat
differ
report
pandem
virusinduc
inflamm
restrict
lung
document
massiv
increas
indic
lung
inflamm
follow
treatment
virtual
system
inflamm
note
fig
similarli
treatment
nthi
lysat
induc
system
leukocytosi
data
shown
despit
profound
cellular
infiltr
induc
lung
presum
confin
respons
lung
explain
lack
morbid
observ
mice
treat
acut
even
high
dose
nthi
lysat
base
observ
conclud
influenza
pneumonia
kill
via
excess
pulmonari
inflamm
progress
deficit
effect
inflamm
addit
exuber
lung
inflamm
secondari
bacteri
infect
often
consid
import
contributor
influenzarel
mortal
interestingli
demonstr
host
respons
bacteri
product
actual
enhanc
clearanc
viral
pathogen
fig
shown
bacteria
viral
infect
may
impair
antibacteri
interferonc
respons
observ
evid
respons
bacteri
lysat
imped
either
type
type
ii
interferon
signal
rather
respons
bacteri
product
seem
reinforc
protect
antivir
event
via
vigor
interferon
gene
express
epidem
respiratori
infect
previous
observ
influenza
sar
result
high
mortal
sometim
pathogen
identifi
often
without
effect
postexposur
treatment
option
season
influenza
though
casemort
rate
lower
still
kill
ten
thousand
american
annual
clinician
face
problem
ineffect
vaccin
strategi
declin
effect
neuraminidas
inhibitor
situat
rapidli
dispers
broad
protect
would
highli
advantag
present
primari
mean
contain
spread
influenza
prevent
expos
individu
develop
diseas
use
trival
hemagglutinin
subunit
vaccin
liveattenu
trival
vaccin
coordin
unit
state
center
diseas
control
prevent
strategi
limit
fact
preval
potenti
pandem
strain
may
accur
predict
inclus
annual
vaccin
normal
adapt
immun
requir
protect
includ
strain
develop
immun
take
week
potenti
obviat
benefit
set
rapidli
spread
outbreak
studi
show
singl
treatment
nthi
lysat
suffici
prevent
otherwis
fatal
influenza
pneumonia
fig
aerosol
lysat
also
administ
repetit
model
sustain
protect
would
clinic
desir
influenza
epidem
tachyphylaxi
influenzaprotect
effect
observ
success
administr
fig
despit
fact
rise
lung
lavag
neutrophil
induc
aerosol
lysat
becom
less
repeat
administr
find
consist
develop
toler
inflammatori
effect
innat
immun
stimul
without
loss
antimicrobi
effector
function
recent
describ
altern
progress
reduct
inflamm
could
reflect
temper
innat
immun
respons
adapt
immun
cell
becom
engag
repetit
stimul
addit
prevent
benefit
nthi
lysateinduc
stir
show
stimul
lung
innat
immun
therapeut
combin
antivir
medic
influenza
infect
improv
surviv
either
treatment
alon
fig
current
prior
work
report
modest
surviv
benefit
lysat
deliv
h
infect
howev
found
continu
induct
antimicrobi
inflammatori
lung
environ
h
potenti
effect
high
dose
ribavirin
almost
complet
avert
otherwis
uniformli
fatal
outcom
zheng
colleagu
recent
report
improv
influenza
surviv
antiviralantiinflammatori
combin
zanamivir
celecoxib
mesalazin
believ
current
studi
first
demonstr
dramat
protect
improv
surviv
antivir
combin
known
induc
inflamm
seem
contradict
result
may
best
resolv
hypothesi
antiinflammatori
regimen
diminish
toxic
associ
uncontrol
immun
respons
ie
reduc
harm
inflamm
proinflammatori
combin
promot
robust
gener
defens
effector
ie
enhanc
protect
inflamm
summari
shown
stimul
lung
mucos
innat
immun
complex
bacteri
lysat
confer
strike
protect
virul
viral
pathogen
resist
influenza
stimul
despit
profound
induct
lungrestrict
inflamm
suggest
excess
pulmonari
inflamm
primari
caus
influenzainduc
mortal
found
treatment
combin
postexposur
set
antivir
medic
improv
surviv
taken
togeth
infer
therapeut
manipul
stir
may
possibl
reduc
mortal
burden
associ
viral
pneumonia
potenti
protect
popul
bioterror
attack
six
eight
week
old
nih
swisswebst
mice
charl
river
use
viral
challeng
protect
studi
mice
divid
group
mice
viru
lung
titer
surviv
bronchoalveolar
lavag
assay
addit
mice
ad
group
six
eight
week
old
mice
use
gene
express
analysi
mice
per
condit
mice
handl
accord
protocol
approv
institut
anim
care
use
committe
baylor
colleg
medicin
univers
texasmd
anderson
cancer
center
euthan
distress
nontyp
haemophilu
influenza
nthi
store
grown
harvest
describ
cell
pellet
wash
resuspend
ml
sodium
chlorid
solut
suspens
pass
three
time
emulsiflex
cell
disruptor
avestin
greater
psi
dilut
mgml
sodium
chlorid
solut
bicinchonin
assay
pierc
centrifug
min
supernat
collect
protein
concentr
adjust
mgml
lysat
steril
passag
mm
filter
frozen
ml
aliquot
treatment
mice
aerosol
lysat
perform
describ
deliv
ml
suspens
min
exposur
clinic
isol
influenza
ahong
hk
mous
lung
pool
viru
passag
least
nine
time
mice
store
frozen
stock
tcid
ml
supernat
mous
lung
homogen
stock
dilut
gelatin
eagl
minim
essenti
medium
sigmaaldrich
aerosol
min
achiev
ld
ld
target
tdic
mous
viral
concentr
nebul
aerosol
lung
homogen
determin
hemagglutin
assay
infect
mdck
cell
experi
g
ribavirin
dissolv
ml
nthi
lysat
prior
aerosol
final
ribavirin
lysat
protein
concentr
mgml
mgml
respect
mice
challeng
without
pretreat
follow
pretreat
day
follow
pretreat
day
day
group
mice
expos
viral
aerosol
day
mice
group
sacrif
lung
remov
lung
homogen
beadbeat
level
viru
determin
remain
mice
group
observ
daili
day
overt
ill
morbid
mortal
mice
weigh
day
three
time
weekli
day
day
character
inflammatori
host
respons
treatment
andor
infect
lung
lavag
cell
count
perform
describ
order
assess
respons
nthi
lysat
treatment
lavag
sampl
unchalleng
mice
obtain
h
final
nthi
lysat
treatment
order
collect
sampl
acut
virusinduc
ill
lavag
sampl
also
collect
day
follow
infect
influenza
multiplex
elisa
cytokin
analysi
perform
searchlight
protein
array
analysi
pierc
biotechnolog
total
leukocyt
count
determin
hemacytomet
differenti
count
cytocentrifug
ml
bronchoalveolar
lavag
fluid
min
follow
wrightgiemsa
stain
better
understand
gene
express
respons
treatment
mice
treat
aerosol
nthi
lysat
euthan
h
h
comparison
untreat
mice
reduc
lung
leukocyt
burden
pulmonari
vasculatur
perfus
airway
lavag
pb
lung
mechan
homogen
total
rna
isol
lung
homogen
use
rneasi
system
qiagen
crna
synthes
amplifi
equal
mass
total
rna
use
ilumina
totalprep
rna
amplif
kit
ambion
amplifi
crna
hybrid
label
sentrix
express
beadchip
illumina
scan
beadstat
illumina
primari
microarray
data
deposit
ncbi
gene
express
omnibu
http
wwwncbinlmnihgov
geo
consist
miam
standard
geo
access
primari
signal
intens
normal
within
sampl
differenti
express
gene
identifi
base
signal
chang
intersampl
variat
gene
ontolog
analysi
perform
use
niaid
databas
annot
visual
integr
discoveri
david
kegg
databas
genomenet
differenti
express
gene
map
signal
pathway
use
ingenu
pathway
analysi
ingenu
system
pathway
nodul
individu
review
mice
use
gene
express
studi
demonstr
similar
nthi
lysat
induc
protect
investig
pathogen
genet
manipul
mice
author
plan
use
dissect
mechan
stir
primarili
background
character
interferonrel
gene
express
chang
induc
nthi
tabl
present
list
gene
contain
transcript
ingenu
pathway
analysi
canon
interferon
signal
pathway
detect
interferonrel
jakstat
transcript
kegg
addit
interferon
relat
transcript
identifi
author
baselin
signal
intens
valu
assign
undetect
control
transcript
order
avoid
report
infinit
fold
chang
valu
summari
statist
viru
lung
tissu
compar
use
student
ttest
proport
mice
surviv
pathogen
challeng
compar
use
fisher
exact
text
logrank
comparison
surviv
distribut
perform
use
kaplanmei
estim
data
shown
repres
least
two
independ
experi
combin
analysi
modest
differ
viru
challeng
dose
analys
perform
use
sasstat
sa
institut
gene
express
analys
treat
untreat
sampl
compar
identifi
treatmentinduc
gene
express
use
anovabas
scheme
written
r
free
softwar
foundat
boston
util
illumina
librari
develop
simon
lin
northwestern
univers
chicago
il
